Volunteers required for CLL research intervie... - CLL Support

CLL Support

23,339 members40,048 posts

Volunteers required for CLL research interviews of relapsed and refractory UK members.

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin
0 Replies

Are you able to take part in a study on Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell

Lymphoma (MCL). Thanks to your help the research company have reached their quota for 'watchful waiting' patients (not currently on treatment).

The researchers are now looking to schedule patients whose condition has relapsed as well as refractory patients (disease did not respond to treatment or returned in less than six months).The researchers are also looking to speak to care givers of this group

This is not a clinical trial,

rather asking patients and carers about their experiences of the various stages

of the disease and treatment.

This may involve face-to-face interviews in central London offices on Monday 21st

of October and also webcam interviews that run on Tuesday 22nd October, Thursday 24th

October and Friday 25th October.

*Pre task - a short homework assignment to be done in preparation for the interview.

Respondents will be required to compile a collage of images or pictures (from any

source) that represent their experience from diagnosis to present.

Rather than post all of the details here, please contact me through a private message and I will provide you with more detail and connect you with the research team.

Nick

CLL Support Association

Written by
HAIRBEAR_UK profile image
HAIRBEAR_UK
Founder Admin
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Reflections from Cardiff, news of CLL research and the changing trials landscape

Hi everyone After reflecting on yesterday's Cardiff CLLSA patient meeting and...
HAIRBEAR_UK profile image
Founder Admin

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent...
Jm954 profile image
Administrator

Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis

Given the interest in my recent response to @[571533] about whether our immune system will get...
AussieNeil profile image
Partner

BTK Degrader Shows Potential for Treating Refractory CLL and SLL

A novel Bruton's tyrosine kinase (BTK) degrader, NX-2127, has shown potential for treating patients...
Jm954 profile image
Administrator

Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL

Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
lankisterguy profile image
Volunteer